# The surgical management of women with ovarian cancer in the south west of England

#### A Olaitan<sup>1</sup>, J Weeks<sup>2</sup>, A Mocroft<sup>3</sup>, J Smith<sup>1</sup>, K Howe<sup>1</sup>, and J Murdoch<sup>1</sup>

<sup>1</sup>Department of Gynaecological Oncology, St Michael's Hospital, Southwell Street, Bristol, BS2, 8EG; <sup>2</sup>Regional Cancer Organisation, Avon Health Authority; <sup>3</sup>Department of Primary Care & Population Sciences, Royal Free & University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK

**Summary** The surgical management of epithelial ovarian cancer in the South West of England was studied in the two years 1997–1998 in order to determine the factors that influence the outcome of surgery and to provide a baseline from which to assess the effect of centralisation of cancer services. All hospitals in the South West region of England participating in the Regional Cancer Organisation's longitudinal study of outcomes in gynaecological malignancies are included. Six hundred and eighty-two patients with epithelial ovarian cancer were registered with the RCO in the two-year study period. Five hundred and ninety-five women were offered primary cytoreductive surgery of which 438 were said to be optimally cytoreduced. Applying multivariate models to analyse the outcome of surgery, older patients (OR = 0.82 per 5-year increase in age, P = 0.0003), patients treated in hospitals managing fewer than ten cases of ovarian cancer per year (OR = 1.92, P = 0.02) and patients with FIGO stage 3 (OR = 0.02, P < 0.0001) or 4 (OR = 0.002, P < 0.0001) disease were less likely to be optimally cytoreduced. Gynaecological oncologists were 2.06 times more likely to attain optimal cytoreduction when compared to general gynaecologists and this was statistically significant (P = 0.01). The results from this study support the argument that limiting surgery for ovarian malignancy to specialised surgeons improves the extent of cytoreductive surgery. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: ovarian cancer; surgery; cytoreduction; gynaecological oncologist

#### INTRODUCTION

The publication of the Calman-Hine Report (Department of Health, 1995) on the commissioning of cancer services has focused attention on the organisation of services for gynaecological cancer. Gynaecological cancers are, by definition, rare cancers and it has been advocated that the centralisation of services will lead to improved quality of care. This assertion has been supported by several recent publications (Jackson et al, 1997), particularly relating to ovarian cancer (Junoer et al, 1994; Kehoe et al, 1994). Ovarian cancer, the commonest gynaecological cancer, has a poor outcome, with a five-year survival of 30-40% (Nguyen et al, 1993). This has been attributed, in part, to late presentation of disease, with the majority of cases having extra-ovarian spread at diagnosis (Nguyen et al, 1996). The principles employed in the treatment of epithelial ovarian cancer are consensus rather than research-based and involve surgical resection of the disease, followed by chemotherapy. Prescribed optimal cytoreductive surgery, which involves reducing the disease to less than 2 cm, can be particularly challenging in cases of advanced ovarian cancer. Previous publications have demonstrated that Gynaecological Oncological surgeons achieve better outcomes in terms of smaller residual disease after surgery (Junor et al, 1994) and improved survival (Kehoe et al, 1994; Junor et al, 1999) than their general gynaecological or surgical colleagues.

The South West region of England is a large geographical region, stretching 220 miles from Gloucester in the north of the

Received 4 September 2000 Revised 17 September 2001 Accepted 3 October 2001

Correspondence to: A Olaitan

region to Penzance at its southernmost tip. The region is served by five cancer centres: Three Counties Centre to the north of the region which serves Cheltenham. Gloucester and Hereford hospitals; Avon and Somerset cancer centre based in Bristol; Exeter and Plymouth cancer centres in the south west of the region and Dorset in the south east. Wiltshire became a part of Avon and Somerset cancer centre at the end of 1998 (See Appendix 1). The current organisation of gynaecological cancer services in the South West of England is similar to the rest of the country. The regional cancer centre receives primary referral from its catchment population and tertiary referrals of more complicated or relapsed cases from associated cancer units and district hospitals. Most ovarian cancer cases receive their primary treatment in their local hospital and are referred centrally if they require further surgery or chemotherapy. This arrangement may change in the near future following the implementation of the recently published National Health Service Executive document 'Improving Outcomes in Gynaecological Cancer' (NHS Executive, 1999). In this document, it has been advocated that all women with ovarian cancer be referred to recognised cancer centres so that they can receive optimal management for their disease, with multidisciplinary input into the planning of their management, expert surgery and chemotherapy from dedicated gynaecological surgeons and oncologists.

There are particular challenges to developing this model of care in a region with a widespread rural population. We therefore decided to study the surgical management of epithelial ovarian cancer in the South West of England in the two years 1997–1998

On behalf of: South and West Tumour Panel for Gynaecological Cancer R Anderson, P Bliss, I Boyd, T Clarke, R Counsell, J Cullimore, F Daniel, A Falconer, E Gilby, J Giles, J Graham, L Hirschowitz, A Hong, N Johnson, V Laurence, R Marshall, JB Murdoch, J Orford, JN Renninson, J Richardson, G Swingler

prior to the re-organisation of gynaecological cancer services, looking particularly at factors influencing the completeness of surgery at each stage of disease. This study, as well as providing a base-line against which future performance can be measured, enables us to estimate the increase in work load and the resource implications for the regional cancer centre if centralisation of ovarian cancer management is fully implemented.

#### MATERIALS AND METHODS

The South and West Regional Cancer Organisation (RCO) Gynaecology Tumour Panel is constituted of a multidisciplinary team of experts involved in the management of gynaecological malignancies. In 1997, the RCO initiated a prospective longitudinal study of the management of gynaecological cancer to establish current patterns of care and facilitate development of services in the region (Jackson et al. 1997). A one-page minimum data-set for each major gynaecological cancer site was designed (Figure 1). After obtaining approval from all units managing gynaecological malignancies, copies of the minimum data set pro forma were circulated along with guidance notes that included outlines of American Society of Anesthesiologists (ASA) grading, FIGO staging, and histopathology information required. Treatment policies detailing accepted pre-operative and operative management of epithelial ovarian cancer were produced and circulated by the RCO to all participating hospitals (Appendix 1). To ensure uniform histopathological reporting, the RCO also circulated guidelines for participating histopathologists (Appendix 2). The clinician managing the case is responsible for filling the form and for returning a copy to the RCO. The data are then entered on a central Microsoft Access<sup>TM</sup> database managed by one of the co-authors (JW). Complete data on surgical procedures are available for 1997 and 1998.

Data for all ovarian cancer cases registered with the RCO from January 1997 to December 1998 were obtained from the RCO database. Central validation by the RCO had previously confirmed registration rates of close to 100% for all hospitals participating in 1997 (Regional Cancer Organisation, 1999). To ascertain completeness of the data and to identify outstanding cases not registered with the RCO, the histopathology departments of participating hospitals were approached for lists of patients with a histological diagnosis of ovarian cancer during the study period. Any cases thus identified were checked with the appropriate clinician, yielding some additional registrations.

The total number and FIGO stage of epithelial ovarian cancer cases managed by each contributing hospital per year was calculated. The accuracy of the FIGO stage was examined by comparing the ascribed FIGO stage with the clinico-pathological data supplied on the RCO form. These details were checked against the specialisation of the surgeon responsible for the case. Cases were re-staged by one of the authors (AO) if there was a mismatch between ascribed FIGO stage and the clinico-pathological data available. Where no FIGO stage was stated, patients were allocated a stage where there was sufficient staging information supplied on the RCO form. Sub-stages were ascribed or confirmed where this information was available. Cases were left without a clinical stage where there was insufficient clinico-pathological information available. Cases were also left unstaged where there was insufficient information to confirm the original FIGO stage allocated. The amended FIGO staging was applied in all subsequent analysis.

All cases undergoing primary surgery were classified according to extent of surgery per stage of disease. Patients with less than 2 cm residual disease at the end of surgery were classified as receiving optimal cytoreductive surgery while those with greater than 2 cm residual disease were classified as receiving suboptimal surgery.

#### Statistical methods

Univariate and multivariate logistic regression analyses were applied to determine the factors related to both the decision to offer surgery and on the outcome of surgery. The factors investigated included age, ASA grade, stage of disease, grade and specialisation of surgeon, consultant supervision, and the number of ovarian cancer operations per contributing hospital per year (classified as 10 or fewer cases of ovarian cancer per year or greater than 10 cases per year).

The operating surgeons were classified as general surgeons, general gynaecologists and gynaecological oncologists according to the information supplied on the RCO form. A gynaecological oncologist was defined as an RCOG-recognised sub-speciality trained individual (of which there is one in the region) or the lead Consultant for gynaecological oncology within a cancer centre. In addition, lead clinicians for gynaecological cancer within teaching or district hospitals with a large caseload (15 or more cases of ovarian cancer per surgeon per year) were included in this definition, giving a total of nine gynaecological oncologists within the region.

#### RESULTS

A total of 820 ovarian cancer cases were registered with the RCO in the study period 1997-1998 from 20 NHS and eight private hospitals. Of these, 36 were non-epithelial tumours. Non-epithelial cancers are not considered in this study and have been excluded from all further analyses. A further eight cases were excluded as they had secondary ovarian tumours from a non-gynaecological primary. Other exclusions included 15 patients with sychronous primaries, the second tumour being non-ovarian and 21 patients who were registered with recurrent ovarian cancer. Of the 740 remaining patients, 58 were registered by hospitals outside the south west region where we were unable to crosscheck the number of ovarian cancer cases with the histopathology department. These patients were therefore also excluded, leaving a total of 682 cases registered with the RCO with a verified diagnosis of primary epithelial ovarian cancer. This number included 129 cases of borderline epithelial tumours. The median age of these patients was 62 years (range 18-94). Figure 2 illustrates the total number of cases registered by each hospital per year. Some hospitals only started to register gynaecological cancer cases with the RCO in 1998 and this is reflected in the relatively small number of cases registered. A total of 94 surgeons, including seven general surgeons and one breast surgeon managed these cases. The median number of cases managed per surgeon over the two-year study period was four (range 1–72). Figure 3 illustrates the number of ovarian cancer cases undertaken by the lead clinician for gynaecological cancer services in each contributing hospital in the two year study period. The Dorset hospitals (see Appendix 1) are not included in this figure as they only started to register cases with the RCO in 1998.


Eighty-nine patients were re-staged because the clinicopathological information given on the RCO form did not match the FIGO stage ascribed while there were 132 cases where there was insufficient data to confirm or assign a stage, making a total of 221


SURGERY         Constitient Surgeon:           Patient in Trial:         yes   no           Trial Name             ASA grade	
Main treatment:       asgreg       asliciturary       cherothetray       Hoopinal       Main treatment         Pattern in Trial:       yes       aso       Trial Name	
SURGERY Consultant Surgeon:         Paieri in Tink:       yp:       no:       Tink Name         ASA grade       Which ovarian cancer operation is this: 1st 2nd 3nd 4fb heision: vertical Asster present and samplet: yp:       no:       Size of Largest transaut ORGANS INVOLVED         ORGANS INVOLVED       Recary:       yp:       no:       Size of Largest transaut ORGANS INVOLVED         Recary:       yp:       no:       don't know       Abdeminate president transaut ORGANS INVOLVED         Recary:       yp:       no:       don't know       Abdeminate president transaut ORGANS INVOLVED         Recary:       yp:       no:       don't know       Abdeminate president transaut ORGANS INVOLVED         Recary:       yp:       no:       don't know       Rectary:       yp:       no:         Preside and the invo       Statil Boxet:       yp:       no:       don't know       Lower statact         Appendix:       yp:       no:       don't know       Statil Boxet:       yp:       no:       don't know       Lower statact         Appendix:       yp:       no:       don't know       statact       Lower statact         Appendix:       yp:       no:       don't know       statact       Lower statact         ROCEEURE       Weide potepot	Postcode
Patient in Trial       yss       no       Trial Name	reatment started / /
Patient in Trial       yss       no       Trial Name	man and a second se
ASA grade       Which ovarian cancer operation is thit: Ist   2nd   3nd   4ft         Incision: vertical         Ascing present and sampled: yes   no         Wachings takes (if no accles); yes   no   don't know         Public periodename         Ascing present and sampled: yes   no         Machings takes (if no accles); yes   no   don't know         Aboring periodename         Covary:       yes   no   don't know         Ascending color:       yes   no   don't know         Aboring periodename         Lowary:       yes   no   don't know         Ascending color:       yes   no   don't know         Aboring periodename         Lowary:       yes   no   don't know         Stau Blowel:       yes   no   don't know         Abore arface:         Appendix:       yes   no   don't know         yes   no   don't know         Liver parendiyma:         Prisipasa-actin coles sampled:       yes   no         Prisipasa-actin coles sampled:       yes   no           PROCEDURE       Wedge biopsy of ovary         stab hotal hysterectory         ormentactory         arrestactory           ROUCEDURE       Wedge biopsy of ovary         stab hotal hysterectory         arrestactory         no           ROUCEDURE       Wedge biopsy of ovary         stab hotal hysterectory         arrestactory         arrestactory           ROUCEDURE       Wedge biopsy efformere nand infinite       stab hotal hyst	
Aseite poerer and surplet: yes   no   Wakings takes (if no acciss): yes   no   Size of largest tensor ORGANS INVOLVED R vary: yes   no   don't know   Ascending color: yes   no   don't know   Price perionents: Largest yes   no   don't know   Decending color: yes   no   don't know   Liver parentsprace Darentsur: yes   no   don't know   Decending color: yes   no   don't know   Liver parentsprace Darentsur: yes   no   don't know   Satall Bowel: yes   no   don't know   Liver parentsprace Price positive   yes   no   don't know   Satall Bowel: yes   no   don't know   Liver parentsprace Price positive   yes   no   don't know   Satall Bowel: yes   no   don't know   Liver parentsprace Price positive   yes   no   den't know   Satall Bowel: yes   no   don't know   Liver parentsprace Price positive   yes   no   den't know   Satall Bowel: yes   no   don't know   Liver parentsprace Price   yes   no   den't know   Satall Bowel: yes   no   don't know   Liver parentsprace Price   yes   no   den't know   Satall Bowel: yes   no   don't know   Liver parentsprace Price   yes   no   den't know   Satall Bowel: yes   no   don't know   Interestion   Price   yes   no   den't know   Satall Bowel: yes   no   don't know   Price   yes   no   den't know   Satall Bowel: yes   no   don't know   Price   yes   no   den't know   Satall Bowel: yes   no   don't know   Price   yes   no   den't know   Satall Bowel: yes   no   don't know   Price   yes   no   den't know   Satall Bowel:   yes   no   don't know   Price   yes   no   yes   for   Price   don't know   Price   don   yes   no   Price   differentiation   well   Price   don't know   Price   differentiation   well   Price   don't know   Price   find   walking segary   yes   no   Price   find   decorrece   yes	transverse 🗌 lagarosopic
ORGANS INVOLVED         Roay:       yes:       ao:       don't know       Averaling color:       yes:       ao:       don't know       Abdenital perimeare:         Loway:       yes:       ao:       don't know       Abdenital perimeare:       Abdenital perimeare:         Loway:       yes:       ao:       don't know       Abdenital perimeare:         Loway:       yes:       ao:       don't know       Abdenital perimeare:         Loway:       yes:       ao:       don't know       Schlightragmic perimeare:         Loway:       yes:       ao:       don't know       Schlightragmic perimeare:         Directain:       yes:       ao:       don't know       Low stract         Appendix:       yes:       ao:       don't know       Low stract         Periobana-contic nodes sampled:       yes:       no:       how strates and       Don't know       Low strates         LSO       RSO       biopy of ovary       and bysterectory       oranial beed resection       MAXIMUM SIZE OF RESEDUAL DISEASE MASS:       >2cm       1-2cm       strates and       no:       No:         PRIMARY SURGEON:       Consultant yes:       ao:       Spectrue (Laway):       aisent?       yes:       no:	
Levary: pes do don't know   Trans color: yes   no   don't know   Abdeninal perimenent: Uterna: yes   no   perivisably sensored   Descending color: yes   no   don't know   Subdispingmatic perios Ornerian: yes   no   don't know   Senal Bowel: yes   no   don't know   Liver parenchyma: Privis/para-sontic nodes paipated no   yes (normal)   yes (normal)   Privis/para-sontic nodes sampled: yes   no   PROCEDURE Wedge biopsy of ovary   and hysterectump   orneriachump   ISO   RSO   biopsy ofly   sub-total hysterectump   small bowel reaction   MAXIMUM SIZE OF RESEDUAL DISEASE MASS: >2cm   1-2cm   clim   ni visible   PRIMARY SURGEON: Consultant yes   no   Spikeg (state Year)   Supernited by somalater? yes   no   HISTOPATHIOLOGY Consultant Network   periopentive CA125     HISTOPATHIOLOGY Consultant Mellion   section   ni visible   Privisely of somal is present   absent   some   periopentive CA125     HISTOPATHIOLOGY Consultant Mellion   moderatery   ornerated infiltrated   democycarcinoms   moderatery     Orarian copular surface Transor deposits present   absent   democycarcinoms   moderatery     Orarian copular surface Transor deposits present   absent     Denotum of taken   taken   taken and infiltrated     Perioneal flaid/washings positive   regulive     Other perioneal biopsies/freshings taken   positive   regulive     Perioneal flaid/washings   positive   no	
Darma       yes       no       den't know       Subdiaphragmetic perifice         Omentame       yes       no       den't know       Liver surface         Appendit:       yes       no       den't know       Liver surface         Pelvidpans-sortic nodes sampled:       yes (normal)       yes (normal)       yes (normal)         Pelvidpans-sortic nodes sampled:       yes       no       Appendit:       yes (normal)         LSO       RSO       biops of vary       and hysterecomy       urnal bowd resection         MAXIMUM SIZE OF RESIDUAL DISEASE MASS:       >2cm       i-2cm       clon       no         PRIMARY SURGEON:       Consultant yes       no       Spleag (nate Year)       Spleag (nate Year)       splead file         PRIMARY SURGEON:       Consultant yes       no       Spleag (nate Year)       splead file       no         CXXR againef con ano tot ken       spleag (nate Year)	yes 🗌 no 🗌 don't know
Direction:       yes   no   don't know   Rectam:       yes   no   don't know   Liver surface:         Appendit:       yes   no   don't know   Small Bowel:       yes   no   don't know   Liver parenchyme.         Privicipues-sortic nodes palpatel:       no   yes (romath)   yes (relarged)         Privicipues-sortic nodes palpatel:       yes (romath)   yes (relarged)           PROCEDURE       Wedge biopsy of orary   sub hysterectumy   ornentectumy         ornentectumy         mentions           SIO       RSO       biopsy orall       sub-total hysterectum         ornentectum           MAXIMUM SEE OF RESIDUAL DISEASE MASS:       >2cm   1-2cm   store         supervised by consultant? yes   no         CXE:       acgative   positive   sub-total hysterectum         ornentectum         no         MAXIMUM SEE OF RESIDUAL DISEASE MASS:       >2cm   1-2cm   store   store         supervised by consultant? yes   no         CXE:       acgative   positive   sub-total hysterectum         moderately         no         MAXIMUM SEE OF RESIDUAL DISEASE MASS:       >2cm   1-2cm   store   store         sub-total hysterectum         no         MAXIMUM SEE OF RESIDUAL DISEASE MASS:       >2cm   1-2cm   store   store   store         no       no       no         MAXIMUM SEE OF RESIDUAL DISEASE MASS:       >2cm   store   store   store   store         no       no       no         MAXIMUM SEE OF R	yes 🗔 no 🛄 don't know
Appendit:       yes       no       don't know       Senall Bowel:       yes       no       don't know       Liver pareachyma:         Perkicipana-sortic nodes pulpated       no       yes inormalit       yes intellarged)          Perkicipana-sortic nodes sampled:       yes       no       mail hysterectury       ormestectury       mail hysterectury       ormestectury       mail hysterectury       host       hos	neum: yes 🗌 no 🗌 don't know
Privicipana-aorie nodes palpateit noyes (normal)yes (enlarged) Privicipana-aorie nodes sampled: yes no PROCEDURE Wedge biopsy of ovary and hysterectomy ormentectumy ISO RSO biopsy only and hysterectomy arrall bewel reaction MAXIMUM SIZE OF RESEDUAL DISEASE MASS: >2cm rism is visible RUMARY SURGEON: Consultant yes no Softeg (wate Year) Supervised by measurant? yes no RECOMMARY SURGEON: Consultant yes no Supervised Dy measurant? yes no REMARY SURGEON: Consultant yes epithelial tadenokcarcinoma HISTOPATHOLOGY Consultant Histopathelologist: HISTOPATHOLOGY Consultant Histopathelologist: HISTOPATHOLOGY Consultant Histopathelologist: Deviana capadar surface advant epithelial tadenokcarcinoma Divatian capadar surface not taken advant Deviana dispate/ not taken	yes 🗌 no 🗌 don't know
Period reproduction   PROCEDURE Wedge biopsy of ovary anal bysterectory   SO RSO biopsy only   SO RSO   BAXIMUM SEE OF RESEDUAL DISEASE MASS: >2cm   PRIMARY SURGEON: Consultant yes   no SpReg (state Year)   Supervised by one Supervised by one   PRIMARY SURGEON: Consultant yes   no SpReg (state Year)   Supervised by one supervised by one   PRIMARY SURGEON: Consultant yes   INSTOPATIFICIOGY Consultant Histopantbologist:   HISTOPATHOLOGY Consultant Histopantbologist:   Histological differentiation well   Datation apsular surface Timour deposits present   Datation apsular surface taken and infiltrated   Contraiternol Ovary not taken   Perioneal Biopsizes/brashings taken positive   Perioneal Biopsizes/brashings taken positive   ChemotherRAPY Treatment of recurrence   Patient in Trut yes   Responic CK   Patient in Trut yes   So Namber of previses corres   ChemotherRAPY Responic   Responic CK   <	yes 🗌 no 🗌 don't know
ROCEDURE       Wedge biopsy of ovary       avail bysterectory       omentactanty         LSO       RSO       biopsy odly       sub-total hysterectory       small bowel resection         MAXIMUM SIZE OF RESEDUAL DISEASE MASS:       >2cm       1-2cm <tcn< td="">       nil visible         PRIMARY SURGEON:       Consultant yes       no       SpReg (wate Year)       Siepernited by consultant?       yes       no         PRIMARY SURGEON:       Consultant yes       no       SpReg (wate Year)       Siepernited by consultant?       yes       no         PRIMARY SURGEON:       Consultant yes       not       SpReg (wate Year)       Siepernited by consultant?       yes       no         PRIMARY SURGEON:       Consultant yes       not done       Perioperative CA125       no       no         HISTOPATHOLOGY       Consultant Histopathologeist:       Histoidagical differentiation       well       mademicity       no         Outrain capular surface       Tumoar deposits present       abeort       abeort       no       no         Outrain capular surface       Tumoar deposits present       abeort       abeort       no       no         Outrain capular surface       Tumoar deposits present       abeort       regative       no         Outratan       n</tcn<>	
SO       BSO       biopsy oldy       sub-total bysterecorres       small bowel resoction         MAXIMUM SIZE OF RESEDUAL DISEASE MASS:       >2cm       1-2cm       initiality         RIMARY SURGEON:       Consultant yes       no       SpReg (wate Year)       Supervised by consultant?       yes       no         RIMARY SURGEON:       Consultant yes       no       SpReg (wate Year)       Supervised by consultant?       yes       no         RIMARY SURGEON:       Consultant Histopathologist:       Initiality       moderately       initiality         HISTOPATHOLOCY       Consultant Histopathologist:       moderately       Initiality       moderately         Hastology       epithelial turnour of borderine malignary       epithelial (adenovacinoma initiality)       Initiality         Outrian capadar surface       Turnour deposits present       absent       Initiality         Outrian capadar surface       Turnour deposits present       absent       Initiality         Outrian       not taken       taken and infiltantod       taken and infiltantod         Costnatarral Ovary       not taken       nogative       nogative         Datentan       not taken       positive       nogative         Other perioneal biopsies/frashings taken       positive       nogative	23. 12 12
MAXIMUM SIZE OF RESIDUAL DISEASE MASS: >2cm   +2cm   <icm nil="" visible=""  =""  <br="">PRIMARY SURGEON: Consultant yes   no   SpReg (state Year)   Supervised by exeaultant? yes   no   CXR: segative   positive   sespectous   not done   Perioperative CA125   HISTOPATHOLOGY Consultant Histopathologist: Histology efference number       noderately   Patiology efference number       noderately   Ovarian capadar surface   Tamour deposits present   absent   Disentan   not taken   taken and infiltrated   Disentan   not taken   taken and infiltrated   Perioneal fluid/vashings   positive   negative   Disentan   not taken   taken and infiltrated   Perioneal fluid/vashings   positive   negative   Disentan   bowel   live   Other organ involvement   bowel   live   Patient in Trial   yes   so   Trial Name   CHEMOTHERAPY   First Line   yes   so   Trial Name   Perioneal debuking sorgery   yes   so   Namber of previous courses   Perioneal debuking sorgery   yes   so   Namber of previous courses   Perioneal debuking sorgery   yes   so   Namber of previous courses   Perioneal debuking sorgery   yes   so   Namber of previous courses   Patient in Trial   Perioneal   Patient in Trial   Perioneal   Perioneal debuking sorgery   Patient  </icm>	large bowel resoction
RIMARY SURGEON:       Consultant yes       no       SpReg (wate Year)       Supervised by consultant?       yes       no         CXR:       aegative       positive       associants       not done       Perioperative CA125	appendicectomy []
CXR: segative positive suspicessus not done Perioperative CA125         HISTOPATHOLOGY Consultant Histopathologist:         finishingy reference number	
HISTOPATHOLOGY       Consultant Histopathologist:         finishing reference number	
Histology reference number	FIGO Stage
Hisology       epithelial turnour of borderline malignancy         epithelial tadenox/arctinoma           Hisological differentiation       well         moderately           Duratian capsular surface       Tamoar deposits present         absent           Duratian capsular surface       not taken         taken and infitured           Duratian capsular surface       not taken         taken and infitured           Duratian capsular surface       not taken         taken and infitured           Duratian capsular surface       positive         taken and infitured           Contralateral Ovary       not taken         taken and infitured           Contralateral Ovary       not taken         regative           Perionecal fluid/washings       positive         regative           Contralateral Ovary       positive         regative           Contralateral Ovary       positive         regative           Contralateral Divosice/Brushings taken       positive         regative           Other organ involvement       bowel         liner           Other organ involvement       position Oncologists!       regative           Patient in Trial       yes         so         Namber of previous courses           Chemotrifierapy Regime       so         Namber of previous courses	*******
Hisological differentiation well moderately   Duratian capsular surface Turnour deposits present absent   Directians not taken taken and infilmated   Directians not taken taken and infilmated   Contralisteral Ovary not taken taken and infilmated   Perioseal fluid/washings positive negative   Perioseal fluid/washings positive negative   Cher peritoneal biopsies/breakings taken positive negative   Other organ involvement howel liter   ONCOLOGY Consultant Oncologist: negative   ONCOLOGY Consultant Oncologist: Present   Other organ involvement howel Trial Name   Patient in Trial yes no   ChemotrierRAPY no Namber of previous courses   First Line yes no   Following debuking surgery yes no   Number of cycles CK PR   RADIOTHERAPY Kesponic CK   RADIOTHERAPY RADIOTHERAPY	
Duarian capadar surface Tamoar deposits present absent   Ducentam not taken taken and infiltrated   Ducentam not taken taken and infiltrated   Contralateral Ovary not taken taken and infiltrated   Perioneal fluid/washings positive negative   Perioneal fluid/washings positive negative   Contralateral Ovary not taken negative   Perioneal fluid/washings positive negative   Cher organ involvement bowel negative   Doter organ involvement bowel negative   ONCOLOGY Consultant Oncologist: negative   Patient in Trialt yes no   Patient in Trialt yes no   ChemotinerApy requires of previous courses perious courses   Following debuking sargery yes no   Number of cycles Responic CR   Ration fluerApy Responic CR   Ration fluerApy Responic CR	othermon-epithelial []
Discentian not taken taken and infiltrated   Contralateral Ovary not taken taken and infiltrated   Perionecal fluid/washings positive negative   Perionecal fluid/washings positive negative   Cher perionecal biogsize/brashings taken positive negative   Other organ involvement bowel licer   Other organ involvement bowel licer   Other organ involvement bowel licer   Other organ involvement bowel negative   Patient in Triat yes no   Patient in Triat yes no   Patient in Triat yes no   Polowing debulking surgery yes no   Following debulking surgery yes no   Number of previous courses courses   ChemOTHERAPY no   Number of cycles Kesponic   Regine name	poorly differentiated
Contrabateral Ovary not taken taken and infiburated   Perionecal fluid/washings positive regative   Lymph nodes positive regative   Deter perionecal biopsice/brashings taken positive negative   Other organ involvement howel negative   Iter organ involvement howel negative   ONCOLOGY Consultant Oncologist: negative   Patient in Trial: yes no   CHEMOTHERAPY negative negative   First Line yes no Number of recurrence   Following debuiking surgery yes no Number of previous courses   CHEMOTHERAPY negetive negetive negetive   States and negetive negetive negetive   Regime name	
Perioneal flaid/washings positive   negative	taken and not infiltrated
Lymph nodes positive	taken and not infiltrated
Other peritoneal biopsies/brashings taken positive	
Other organ involvement     howel     liver       ONCOLOGY     Consultant Oncologist:       Patient in Trial:     yes     no       Patient in Trial:     yes     no       CHEMOTHERAPY       TREATMENT INTENT       First Line     yes     no       Following debuiking surgery     yes     no       CHEMOTHERAPY KEGIME     Number of previous courses	not biopsind 🗌
ONCOLOGY Consultant Oncologist:  Patient in Truit. yes _ no _ Trial Name  CHEMOTHERAPY TREATMENT INTENT First Line yes _ no _ Treatment of recurrence yes _ no Following debulking surgery yes _ no _ Number of previous courses CHEMOTHERAPY REGIME Regime name Number of cycles Response CRR RADIOTHERAPY TREATMENT INTENT	
Patient in Tital: yes _ no _ Tital Name	other 🗔
CHEMOTHERAPY TREATMENT INTENT First Line yes no Treatment of recurrence yes no Following debuiking surgery yes 10 0 Number of previous courses CHEMOTHERAPY REGIME Regime name Number of cycles Response CR PR RADIOTHERAPY TREATMENT INTENT	A PROPERTY AND A PROPERTY
TREATMENT INTENT First Line yes no Treatment of recurrence yes no Following debulking sargery yes no Number of previous courses CHEMOTHERAPY REGIME Regime name Number of cycles Response CR PR RADIOTHERAPY TREATMENT INTENT	
First Line yes no Treatment of recurrence yes no Following debuilking surgery yes no Number of previous courses CHEMOTHERAPY REGIME Regime name Number of cycles Response CR PR RADIOTHERAPY TREATMENT INTENT	
Following debulking surgery yes 0 to 0 Number of previous courses CHEMOTHERAPY REGIME Regime name Number of cycles CR PR RADIOTHERAPY TREATMENT INTENT	
CHEMOTHERAPY REGIME Regime name Number of cycles Response CR PR RADIOTHERAPY TREATMENT INTENT	0
Regime nameResponse CR PR Number of cyclesResponse CR PR RADIOTHERAPY TREATMENT INTENT	
Number of cycles Response CR PR RADIOTHERAPY TREATMENT INTENT	
RADIOTHERAPY TREATMENT INTENT	
TREATMENT INTENT	5D PD
RADIOTHERAPY REGIME	

White copy - Return to RCO Yellow copy - Gynaecology notes like copy - Oncology notes Pink copy - Oncologist's records Green copy - Gynaecologist's records

Figure 1 Regional Cancer Organisation Registration Pro forma










Figure 3 Number of ovarian cancer cases/lead clinician in two-year study period

(32.5%) unsatisfactorily staged cases. Table 1 describes the restaging action taken classified according to the specialisation of the surgeon managing the case. Staging was accurate in 81.6% of cases managed by gynaecological oncologists, 62.8% of cases managed by general gynaecologists and 32.1% of cases managed by general surgeons.

Five hundred and ninety-five patients (87.2%) were managed surgically while 69 (9.9%) had laparoscopy and biopsy only. In 438 (81.2%) of the surgical cases, the Consultant was the primary surgeon. In 14 cases, the grade of the primary surgeon was not indicated. The remaining 98 were operated on by surgeons in non-Consultant grades, specialist registrars in the majority of cases. Sixty-two (63.0%) of these procedures were undertaken under Consultant supervision. In all 545 (92%) of procedures were performed by consultants or under consultant supervision. The surgeons undertaking ovarian cancer surgery without supervision included specialist registrars in year 3 (three cases), year 4 (three cases), year 5 (12 cases) and nine cases undertaken by a variety of non-consultant grade surgeons including staff grade doctors.

The amended FIGO stage at presentation of patients who underwent definitive surgery and those who did not is described in Table 2. Table 3 shows the ASA grade of patients undergoing surgery compared with those managed conservatively.

Four hundred and thirty-eight (73.8%) were described as having less than 2 cm of residual disease after surgery while 119 women had more than 2 cm of residual disease. Table 4 describes the FIGO stage at presentation of these patients and the cytoreductive rates tabulated against the operating surgeon's specialisation.

Applying univariate analysis to determine the factors influencing the decision to undertake surgery revealed that patients were less likely to be offered surgery if they were of older age (odds ratio (OR) per 5-year increase in age = 0.89, P = 0.005), in ASA grade 3 or 4 (OR 0.30, P < 0.0001) and had FIGO stage 4 disease at presentation (OR=0.10, P < 0.0001). In multivariate analyses, age was no longer significant, but patients in ASA grade 3 or 4 remained significantly less likely to be offered surgery (OR 0.3, P < 0.0001), as were patients in FIGO stage 4 (OR 0.10, P = 0.0001). In addition, in multivariate analyses, there was no significant difference in the likelihood of undergoing surgery by the

 Table 2
 FIGO stage of ovarian cancer at presentation comparing patients

 who underwent primary surgery with those who did not
 Image: Comparing patients

FIGO Stage	Total no. of cases (%)	Total no. with surgery (%)	Total no. no surgery (%)		
I	156 (22.9)	155 (22.7)	1 (1.2)		
11	51 (07.5)	51 (7.4)	0 (0.0)		
111	318 (46.6)	272 (39.9)	46 (6.7)		
IV	24 (3.5)	13 (1.9)	11 (1.6)		
Unstated	133 (19.5)	104 (15.2)	29 (4.3)		
Total	682 (100)	595 (87.2)	87 (12.8)		

 Table 3
 ASA grades of patients undergoing surgery compared with those who had no surgery

ASA grade	Total no. of cases (%)	Total no with surgery (%)	Total no with no surgery (%)		
1	293 (43.0)	277 (40.6)	16 (2.3)		
2	204 (29.9)	179 (26.2)	25 (3.7)		
3	104 (15.2)	78 (11.4)	26 (3.8)		
4	8 (1.2)	4 (0.6)	4 (0.6)		
not stated	73 (10.7)	57 (8.4)	16 (2.3)		
Total	682 (100)	595 (87.2)	87 (12.8)		

 Table 1
 Amended stage of ovarian cancer classified according to specialisation of responsible surgeon

Specialisation	No Change	Down- staged	Up- staged	Staged	Up-substage	Down-substage	No Stage	Total
Gynae	243	27	10	19	4	5	79	387 (56.7)
Gynae-Onc	199	5	5	5	0	1	29	244 (35.8)
Surgeon	9	2	1	0	0	0	16	28 (4.1)
Not Stated	10	3	1	1	0	0	8	23 (3.4)
Total	461	37	17	25	4	6	132	682
%)	(67.5)	(5.4)	(2.5)	(3.7)	(0.6)	(0.9)	(19.4)	(100)

FIGO stage	Gynaecologist 341		Gynaecological oncologist 219		Surgeon 20			Unstated 15			Total 595		
Total	< 2 cm	> 2 cm	Unst	< 2 cm	>2 cm	Unst.	<2 cm	>2 cm	Unst.	<2 cm	>2 cm	Unst.	
1	94	1	7	46	0	2	1	0	0	1	0	0	152
11	23	1	1	20	0	0	1	0	2	4	0	1	53
III	67	66	7	82	36	6	1	3	1	3	0	1	273
IV	0	6	2	4	0	0	0	0	0	0	0	0	12
Unst.	62	1	5	20	0	1	10	1	0	2	0	3	105
Total	246	75	22	172	36	9	13	4	3	10	0	5	595
%	71.8	22.0	6.2	77.6	18.3	4.1	65.0	20.0	15.0	66.7	0.0	33.3	100

Table 4 FIGO stage of patients undergoing optimal cytoreductive surgery classified according to surgeon's specialisation

Unst = Unstated

caseload of the hospital (OR = 1.01, P = 0.97) or by the specialisation of the surgeon (OR = 1.33, P = 0.32) when comparing gynaecological oncologists with general gynaecologists.

These factors also had an effect on the outcome of surgery. In multivariate models, older patients were less likely to be optimally cytoreduced (OR = 0.82 per 5-year increase in age, P = 0.0003). Similarly patients with FIGO stage 3 (OR = 0.02, P < 0.0001) or 4 (OR = 0.002, P < 0.0001) disease were less likely to be optimally cytoreduced. Patients treated in hospitals managing fewer than 10 cases per year were less likely to be optimally cytoreduced (OR = 1.92, P = 0.02) compared to those treated in hospitals managing 10 or more cases per year. ASA grade appeared to have no effect on the extent of surgery. Gynaecological oncologists were significantly more likely to attain optimal cytoreduction when compared to general gynaecologists (OR = 2.06, P = 0.01) while general surgeons were less likely to attain optimal cytoreduction although this difference was not statistically significant (OR = 0.30, P = 0.18).

# DISCUSSION

The peculiar geography of the South West Region may make centralisation of gynaecological cancer services particularly challenging. The large expanse of rural and sparsely populated land means that there are several hospitals serving relatively small populations. Consequently, the majority of surgeons participating in this survey managed fewer than ten cases of ovarian cancer per year. The median number of cases per surgeon was four and over half of the lead surgeons for cancer services were operating on fewer than ten cases of ovarian cancer per year. The need to maintain a critical volume of work in order to sustain surgical expertise has been extensively discussed (Department of Health 1995; Jackson et al, 1997). Trimbos et al (2000), using surgery for cervical cancer as a model, demonstrated that there is a long learning curve associated with surgery for gynaecological cancer. They demonstrated a reduction in operative blood loss and operating time achieved by the same operating team over a period of thirteen years.

Eighty-nine patients (13%) required re-staging due to discrepancies between the ascribed FIGO stage and the clinico-pathological data supplied on the RCO form. One hundred and thirty-two patients (19.4%) could not be allocated a stage because there was insufficient staging data available on the RCO form. The majority of cases managed by gynaecological oncologists were accurately staged but this proportion was decreased in general gynaecologists and more so for general surgeons where, in the majority of cases, there was insufficient staging information recorded. Accurate staging is of critical importance as the decision about whether to recommend adjuvant therapy is based on this. In addition, analyses of survival data become meaningless if the correct FIGO stage is not established at the outset.

Although the same selection criteria for surgery were apparently applied through all centres, with older, less fit women being less likely to be offered surgery, hospitals that managed more than ten cases of ovarian cancer a year achieved better optimal cytoreduction rates than those managing ten or fewer cases per. In keeping with previous published reports (Junor et al, 1994; Kehoe et al, 1994), sub-specialist gynaecological oncologists achieved significantly better optimal cytoreduction rates than their non-sub-specialist colleagues although the majority of operations were carried out by general gynaecologists. The improved cytoreduction rates achieved by gynaecological oncologists (as defined by this paper) may reflect their higher case volume. There is only one RCOG-recognised subspecialty trained gynaecological oncologist in the region and so the other 'gynaecological oncologists' included in this analysis were defined by their work-load. The more widespread introduction of sub-specialty training in gynaecological oncology will, in future, allow tighter definitions of specialists and consequently, more specific analyses.

Although there are no randomised controlled trials analysing the effect of optimal cytoreductive surgery on median survival, a large number of retrospective studies have documented a favourable prognostic effect on median survival (Hogberg et al, 1993; Marsoni et al, 1990). A meta-analysis of 58 studies showed that maximum cytoreductive surgery produced a small improvement in median survival time (Hunter et al, 1992).

It is of concern that, although this happened infrequently, a number of junior doctors undertook surgery for ovarian cancer without supervision. However, the RCO does not routinely collect data about which cases were undertaken as emergencies and it may be that some of these cases presented acutely and that there was no prior suspicion of cancer. Appropriately, the majority of operations (92%) were undertaken by or supervised by Consultants.

The main drawback of this analysis is the failure to include data on chemotherapy. There is a lag phase of up to six months between surgery and completion of chemotherapy and the data for 1998 are as yet, incomplete. We would aim to include chemotherapy data in our subsequent analysis.

The follow-up period in this study is too short to examine survival, particularly as chemotherapy data are incomplete. However, previous publications (Junor et al, 1999) have shown a survival advantage in patients operated on by gynaecological oncologists over general gynaecologists or surgeons. Longitudinal follow-up is on-going and we should be in a position to analyse survival next year with the advantage of prospectively collected data.

### ACKNOWLEDGEMENTS

This analysis would not have been possible without the co-operation of the Consultants from all participating hospitals who worked hard to ensure that the RCO forms were completed and promptly returned.

#### REFERENCES

- Department of Health, May 1995. A policy framework for commissioning cancer services. Guidance for purchasers and providers of cancer services.
- Hogberg T, Carstensen J and Simonsen E (1993) Treatment results and prognostic factors in a population-based study of ovarian cancer. Gynecol Oncol 48: 38–49
- Hunter RW, Alexander ND and Soutter WP (1992) Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 166: 504-511

- Jackson S, Murdoch J, Howe K et al (1997) The management of cervical carcinoma within the South West region of England. Br J Obstet Gynaecol 104: 140-144
- Junor EJ, Hole DJ and Gillis CR (1994) Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer 70: 363-370
- Junor EJ, Hole DJ, McNulty et al (1999) Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish study of 1866 patients. Br J Obstet Gynaecol 106: 1130-1136
- Kehoe S, Powell J, Wilson S et al (1994) The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. Br J Cancer 70: 1014-1017
- Marsoni S, Torri V, Valsecchi MG et al (1990) Prognostic factors in advanced epithelial ovarian cancer. Br J Cancer 62: 444-450
- Nguyen NH, Averette HE, Hoskins W et al (1993) National survey of ovarian carcinoma IV. Critical assessment of current International Federation of Obstetrics and Gynaecology Staging System. Cancer 72: 3007-3011
- NHS Executive, July 1999. Improving Outcomes in Gynaecological Cancers: Guidance on Commissioning Cancer Services.
- Regional Cancer Organisation, April 1999. Management of Gynaecological Carcinoma in the South West of England. South & West.
- Trimbos JB, Hellebrekers BWJ, Kenter GG, Peters LAW and Zwinderman KH (2000) The long learning curve of gynaecological cancer surgery: an argument for centralisation. BJOG 107: 19-22

APPENDIX 1 Contributing hospitals

	С	ancer Centre 1997	Hospital				
NHS	1	Plymouth	Derriford Plymouth				
	2	Plymouth	Treliske RCH Truro				
	3	Exeter	Exeter RD & E				
	4	Exeter	NDDH Barnstable				
	5	Exeter	Torbay				
	6	3 Counties	CGH Cheltenham				
	7	3 Counties	GRH Gloucester				
	8	3 Counties	Hereford County Hospital				
	9	Avon & Somerset	Bath RUH				
	10	Avon & Somerset	Frenchay Bristol				
	11	Avon & Somerset	MPH Taunton				
	12	Avon & Somerset	Southmead Bristol				
	13	Avon & Somerset	St Michael's Bristol				
	14	Avon & Somerset	Weston General				
	15	Avon & Somerset	Yeovil District Hospital				
	16	Wiltshire	Salisbury (Odstock)				
	17	Wiltshire	Swindon Princess Margaret				
	18	Dorset	Poole Hospital				
	19	Dorset	Royal Bournemouth General				
	20	Dorset	West Dorset Dorchester				
PRIVATE							
	1	Plymouth	Duchy Cornwall				
	2	Exeter	Mount Stuart				
	3	3 Counties	Cotswold Nuffield Royal				
	4	3 Counties	Winfield				
	5	Avon & Somerset	Bath Clinic				
	6	Avon & Somerset	Chesterfield				
	7	Avon & Somerset	Glen Bristol				
	8	Avon & Somerset	Somerset Nuffield				

# SOUTH AND WEST REGIONAL CANCER ORGANISATION

King Square House, King Square, Bristol BS2 8EE

# **HISTOPATHOLOGY GUIDELINES**

#### 1. Cervical carcinoma

- *a)* Squamous carcinoma—this category includes typical squamous carcinomas showing all grades of differentiation and of both large and small cell subtypes. The category also includes papillary squamous carcinomas and condylomatous carcinomas. Micro-invasive carcinomas of squamous type should also be recorded in this category. Verrucous carcinomas (which are invariably well-differentiated) are also of squamous type and should be included in this category. However, since the behaviour of these tumours differs from the other types of squamous carcinoma, in addition to ticking the "squamous" box on the form, please write "verrucous" alongside the box as well.
- b) Adenocarcinoma—adenocarcinomas of endocervical, endometrial papillary serous, clear cell and enteric types are all included in this category as is minimal deviation adenocarcinoma. Early invasive adenocarcinoma should also be recorded.
- c) Other—adenosquamous carcinomas, mixed tumours, small cell carcinomas (basaloid, neuroendocrine), undifferentiated carcinoma, glassy cell carcinoma, adenoid cystic carcinoma and malignant mixed mesodermal (Mullerian) tumours.

# 2. Endometrial carcinoma

- *a)* Usual type—endometrioid adenocarcinomas are deemed to be of "usual type". This category includes endometrioid adenocarcinomas with squamous/morular metaplasia, secretory carcinomas, papillary and ciliated cell variants.
- b) High grade type—this category includes papillary serous adenocarcinomas, clear cell, adenosquamous, squamous and undifferentiated carcinomas.
- c) Other-malignant mixed mesodermal/Mullerian tumours and any other tumours not included in categories a) or b) above.

# 3. Ovarian carcinoma

- *a)* Borderline and invasive epithelial tumours—include serous, mucinous (endocervical and enteric), transitional/Brenner, endometrioid and clear cell/mesonephroid tumours. Undifferentiated carcinomas are also included in the invasive epithelial group.
- b) Other-this category includes all other ovarian tumours (including carcinomas arising in teratomas).

#### 4. Vulval carcinoma

- *a)* Squamous carcinomas—include warty/condylomatous carcinoma, spindle cell squamous carcinomas, scams carcinoma with tumor giant cells and acantholytic squamous cell carcinoma.
- b) Verrucous carcinoma-is listed separately because it differs in clinical behaviour from typical squamous carcinoma.
- *c) Other*—basal cell carcinoma, mixed tumours, Paget's disease, Melanomas, adenocarcinomas arising locally within adnexal or vestibular glands and any type of carcinoma no listed in a) or b) above.